NervGen Pharma Corp. (TSXV:NGEN)

Market Cap	185.06M
Revenue (ttm)	n/a
Net Income (ttm)	-24.01M
Shares Out	70.64M
EPS (ttm)	-0.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,387
Average Volume	25,112
Open	2.620
Previous Close	2.640
Day's Range	2.610 - 2.670
52-Week Range	1.650 - 3.360
Beta	1.18
RSI	35.06
Earnings Date	Apr 3, 2025

About NervGen Pharma

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer’s disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cor...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 7
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: NGEN